SLGL News and Press, Sol-Gel Technologies Ltd. From 11/11/21

Sol-Gel Technologies (NASDAQ:SLGL): Q3 GAAP EPS of $0.05 beats by $0.12. Revenue of $8.83M (+316.5% Y/Y) beats by $1.21M. Press Release For further details see: Sol-Gel Technologies EPS beats by $0.12, beats on revenue

Sol-Gel attains a profitable quarter , reporting total revenues of $ 8.8 million , net income of $1.3 million and EPS of $0. 06 Recently obtained FDA approval of TWYNEO ® trigger s a $ 3.5 milli...

NESS ZIONA, Israel, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the Company will p...

-  Sol-Gel to receive $21 million over 24 months in exchange for the transfer of its rights to two marketed generic drugs and eight unapproved generic programs -  Sol-Gel to retain two generic programs encompassing four high-value generic drug candidates ...

NESS ZIONA, Israel, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the Company will ...

NESS ZIONA, Israel, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the Company will ...

Sol-Gel Technologies (NASDAQ:SLGL): Q2 GAAP EPS of $0.35 beats by $0.56. Revenue of $0.9M (-20.4% Y/Y) misses by $2M. Press Release For further details see: Sol-Gel Technologies EPS beats by $0.56, misses on revenue

Recently obtained FDA approval of TWYNEO ® triggers milestone payment from Galderma Exclusive license agreements with Galderma for U.S. commercialization of EPSOLAY ® and TWYNEO Sol-Gel adv ancing its early-stage pipeline in plaque psoriasis...

Bet_Noire/iStock via Getty Images The U.S. FDA has approved Sol-Gel Technologies' ([[SLGL]]) TWYNEO (tretinoin/benzoyl peroxide) cream, 0.1%/3%, for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older. TWYNEO, which is patent protected until 2038, was a...

TWYNEO ® , a once-daily cream treatment for acne vulgaris, is the first FDA-approved fixed-dose combination of tretinoin and benzoyl peroxide TWYNEO utilizes Sol-Gel’s proprietary microencapsulation technology and is patent protected until 2038 Un...